IGF1 and schizophrenia: The present study extended the observation period and recruited additional participants aiming to determine the differences in serum cortisol and IGF-1 levels between patients with MDD and schizophrenia, while controlling for confounding factors, such as fasting, comorbidities, age, sex, and BMI.